



CFW 1744

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/589,054

Inventors: SOARES, et al

Filed: February 11, 2005

Title: AMYLIN FAMILY PEPTIDES AND METHODS  
FOR MAKING AND USING THEM

Confirmation No.: 5466

TC/A.U.: 1744

Examiner: Not Yet Assigned

Atty. Docket No. 0105US-UTL2

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In compliance with 37 C.F.R. §1.56, the patent documents listed on the attached Form PTO/SB/08A are being submitted herewith for consideration by the Examiner. In accordance with 37 C.F.R. 1.98, a copy of each of the listed items, other than U.S. Patents and U.S. Patent Application Publications, is included herewith. Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08A, indicating that the information has been considered and made of record herein.

The references are being cited only in the interest of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicants believe that it is being filed before the mailing date of the first Office Action

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a 8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date of Deposit

12/12/06

Signature of Person Mailing Paper


Name of Person Mailing Paper

on the merits. Accordingly, neither a statement nor a fee under 37 C.F.R. 1.97(c) is required. If Applicants are mistaken, and the mailing date of the first Office Action on the merits precedes the filing of this Information Disclosure Statement, Applicants authorize that the fee due under 37 C.F.R. 1.17(p) be charged to Deposit Account No 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.


Respectfully Submitted

AMYLIN PHARMACEUTICALS, INC.

Dated: December 12, 2006

  
\_\_\_\_\_  
Karen R. Zachow, Ph.D.  
Registration No. 46,332

**AMYLIN PHARMACEUTICALS, INC.**  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: (858) 552-2200  
Facsimile: (858) 552-1936



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

**Complete if Known**

Application Number	10/589,054
Filing Date	February 11, 2005
First Named Inventor	SOARES, et al
Art Unit	1744
Examiner Name	Not Yet Assigned
Attorney Docket Number	0105US-UTL2

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	001	US- 2003-0026182	02-06-2003	FISCHER, et al	
	002	US- 2003-0092606	05-15-2003	L'ITALIEN, et al	
	003	US- 2004-0022807	02-05-2004	DUFT, et al	
	004	US- 2006-0094652	05-04-2006	LEVY, et al	
	005	US- 2006-0094653	05-04-2006	LEVY, et al	
	006	US- 2006-0135747	06-22-2006	LEVY, et al	
	007	US- 5,124,314	06-23-1992	COOPER	
	008	US- 5,264,372	11-23-1993	BEAUMONT, et al	
	009	US- 5,578,708	11-26-1996	OKAZAKI, et al	
	010	US- 5,686,411	11-11-1997	GAETA, et al	
	011	US- 5,766,627	06-16-1998	SANKARAM, et al	
	012	US- 5,998,367	12-07-1999	GAETA, et al	
	013	US- 6,087,334	07-11-2000	BEELEY, et al	
	014	US- 6,114,304	09-05-2000	KOLTERMAN, et al	
	015	US- 6,143,718	11-07-2000	KOLTERMAN, et al	
	016	US- 6,296,842	10-02-2001	JAWOROWICZ, et al	
	017	US- 6,368,630	04-09-2002	BERNSTEIN, et al	
	018	US- 6,379,703	04-30-2002	LYONS, et al	
	019	US- 6,379,704	04-30-2002	WRIGHT, et al	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	020	EP 289287	01-28-1998	COOPER, et al		
	021	WO 2005/000222	01-06-2005	ONG, et al		
	022	WO 94/26292	11-24-1994	BALASUBRAMANIAM		
	023	WO 96/40196	12-19-1996	RINK, et al		
	024	WO 99/07404	02-18-1999	BEELEY, et al		
	025	WO 99/25727	05-27-1999	BEELEY, et al		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet 2

2

Q

5

**Complete if Known**

Application Number	10/589,054
Filing Date	February 11, 2005
First Named Inventor	SOARES, et al
Art Unit	1744
Examiner Name	Not Yet Assigned
Attorney Docket Number	0105US-UTL2

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				
	030	WO 99/25728	05-27-1999	BEELEY, et al		
	031	WO 99/40928	08-19-1999	BEELEY, et al		
	032	WO 05/77072	08-25-2005	LEVY, et al		
	033	WO 05/77094	08-25-2005	LEVY, et al		
	034	WO 06/66024	06-22-2006	LEVY, et al		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/589,054
		Filing Date	February 11, 2005
		First Named Inventor	SOARES, et al
		Art Unit	1744
		Examiner Name	Not Yet Assigned
Sheet 3	of 5	Attorney Docket Number	0105US-UTL2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	035	BECKER, "Procalcitonin and the Calcitonin Gene Family of Peptides..." J. Clin. Endocrinology & Metabolism, 89(4):1512-1525 (2004)	
	036	BECK-SICKINGER, et al "Complete L-alanine Scan of Neuropeptide Y Reveals Ligands Binding..." Eur. J. Biochem., 223:947-958 (1994)	
	037	BRAY, GA, "Drug Treatment of Obesity", Am. J. Clin. Nutr., 55:538S-544S (1992)	
	038	BRAY, GA, "Treatment for Obesity: A Nutrient Balance/Nutrient Partition Approach" Nutr. Rev. 49:33-45 (1991)	
	039	CAMPFIELD, LA, "Recombinant Mouse OB Protein:Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks" Science, 269:546-549 (1995)	
	040	GIBBS, et al. "Rational Scanning Mutagenesis of a Protein Kinase Identifies Functional Regions Involved in Catalysis and Substrate..." J. Biol. Chem., 266:8923-8931 (1991)	
	041	HALAAS, JL, "Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene" Science, 269:543-546 (1995)	
	042	HILTON, JM, et al "Identification of Key Components in the Irreversibility of Salmon Calcitonin Receptors" The Journal of Endocrinology, Vol. 166, No. 1, pgs 213-226 Jul 2000	
	043	JUNG, RT, "The Management of Obesity" Clin. Endocrinol. (Oxf.) 35:11-20 (1991)	
	044	KUCZMARSKI, "Prevalence of Overweight and Weight Gain in the United States" Amer. J. of Clin. Nut., 55:495S-502S (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/589,054
		Filing Date	February 11, 2005
		First Named Inventor	SOARES, et al
		Art Unit	1744
		Examiner Name	Not Yet Assigned
Sheet 4	of 5	Attorney Docket Number 0105US-UTL2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	045	KUESTNER, RE, "Cloning and Characterization of an Abundant Subtype of the Human Calcitonin Receptor" Mol. Pharmacol., 46:246-255 (1994)	
	046	KURIHARA, H, "Targeted Disruption of Adrenomedullin and alphaCGRP Genes Reveals Their Distinct Biological Roles" Hypertens Res., 26 Suppl S (Feb 2003)	
	047	LEE, et al, "Successful Weight Loss with Protein-Sparing Modified Fast in a Morbidly Obese Boy..." Clin. Pediatr. 31:234-236 (April 1992)	
	048	LYZNICKI, JM, "Obesity:Assessment and Management in Primary Care" Am. Fam. Physician, 63:2185-2196 (2001)	
	049	MATSUSHITA, et al, "Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Botrocetin..." J. Biol. Chem., 275:11044-11049 (2000)	
	050	MORLEY, et al "Modulation of Food Intake by Peripherally Administered Amylin" Am. J. Physiol. 267:R178-R184 (1994)	
	051	MORRISON, et al "Combinatorial Alanine-Scanning" Curr. Opin. Chem. Biol. 5:302-307 (2001)	
	052	MUFF, et al "Comparison of a Calcitonin Gene-related Peptide Receptor in a Human Neuroblastoma Cell Line..." Ann. NY Acad. Sci. 657:106-116 (1992)	
	053	PELLEYMOUNTER, et al "Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice" Science 269:540-543 (1995)	
	054	POYNER, et al "Structural Determinants for Binding to CGRP Receptors Expressed by Human SK-N-MC and Col 29 Cells..." British J. of Pharm. 124(8):659-1666 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/589,054
		Filing Date	February 11, 2005
		First Named Inventor	SOARES, et al
		Art Unit	1744
		Examiner Name	Not Yet Assigned
Sheet 5	of 5	Attorney Docket Number	0105US-UTL2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	055	REEDER, et al "Obesity and its Relation to Cardiovascular Disease Risk Factors in Canadian Adults" Can. Med. Assoc. J. 146(11):2009-2019 (1992)	
	056	RISSANEN, et al "Risk of Disability and Mortality Due to Overweight in a Finnish Population" BMJ 301:835-837 (1990)	
	057	SANDBERG, et al "New Chemical Descriptors Relevant for the Design of Biologically Active Peptides..." J. Med. Chem.41:2481-2491 (1998)	
	058	SEXTON, et al "Calcitonin" Current Medicinal Chemistry 6:1067-1093 (1999)	
	059	SURWIT, et al "Differential Effects of Fat and Sucrose on the Development of Obesity and Diabetes..." Metabolism 44:645-651 (1995)	
	060	WEINTRAUB, et al "Drug Treatment of Obesity" Medical Clinics of North America 73(1):237 (1989)	
	061	WIMALAWANSA "Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily" Crit. Rev. Neurobiol. 11:167-239 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/589,054

Inventors: SOARES, et al

Filed: February 11, 2005

Title: AMYLIN FAMILY PEPTIDES AND METHODS  
FOR MAKING AND USING THEM

Confirmation No.: 5466

TC/A.U.: 1744

Examiner: Not Yet Assigned

Atty. Docket No. 0105US-UTL2

TRANSMITTAL

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The following documents are enclosed herewith for your review and consideration:

- Information Disclosure Statement 2 pages
- PTO Form SB/08 5 pages
- Copies of References cited (38 references)
- Return Receipt Postcard

Total (including this page) 8 pages

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

Dated: December 12, 2006

By: Karen R. Zachow  
Karen R. Zachow, Ph.D.  
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.  
9360 Town Centre Drive  
San Diego, CA 92121  
Telephone: 858.552.2200  
Facsimile: 858.552.1936

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231

12/12/06  
Date of Deposit

Deborah Wykes  
Name of Person Mailing Paper  
Deborah Wykes  
Signature of Person Mailing Paper